Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 70

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 70
---
ernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Changes in Stockholders' Equity 

(unaudited, in thousands, except share data)

Common StockAdditional Paid-in CapitalAccumulated OtherComprehensiveEarnings (Loss)RetainedEarningsTotalStockholders'EquitySharesAmountBalance, December 31, 202354,723,356 $55 $439,493 $(593)$482,561 $921,516 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 5,897 — — 5,897 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld241,960 — 1,570 — — 1,570 Net earnings— — — — 124 124 Unrealized gain on marketable securities, net of tax— — — 59 — 59 Balance, March 31, 202454,965,316 $55 $446,960 $(534)$482,685 $929,166 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 6,552 — — 6,552 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld80,733 — 1,658 — — 1,658 Net earnings— — — — 19,916 19,916 Unrealized gain on marketable securities, net of tax— — — 162 — 162 Balance, June 30, 202455,046,049 55 455,170 (372)502,601 957,454 

See accompanying notes.

7

 Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)Six Months Ended June 30,20252024(unaudited)Cash flows from operating activitiesNet earnings$10,672 $20,040 Adjustments to reconcile net earnings to net cash provided by operating activities:Depreciation and amortization41,741 41,467 Amortization of premium/discount on marketable securities(1,106)1,531 Change in fair value of contingent consideration7,660 (5,450)Share-based compensation expense15,575